Wearables Useless on Hormonal Therapy GLP-1 Fluctuating Hormones

That little red or green number your wearable gives you every morning isn't the objective truth. You know this, intellectually. Yet you still feel that small drop in your stomach when the ‘readiness’ score is low, as if a tiny, wrist-mounted bureaucrat has denied your application for a productive day. The problem is, for a vast and growing number of us—anyone on GLP-1 agonists, hormonal contraception, HRT, or simply navigating the shifting tides of a menstrual cycle—that bureaucrat is reading from an outdated manual. Your device is a fixed-scale ruler trying to measure a floor that moves, so the readout it gives you is often hormonal noise, not recovery signal.

Common Questions

Why does my wearable give me weird readings on HRT or GLP-1s?

These therapies alter your physiological baseline, particularly your resting heart rate (RHR) and heart rate variability (HRV). Hormones and drugs like semaglutide directly influence your autonomic nervous system. Your device’s algorithm, built on population averages, sees a new baseline as a deviation—penalising you for a change it can't contextualise.

Is HRV data useless if my hormones fluctuate?

It’s not useless, but it’s certainly not a straightforward 'readiness score'. You can no longer take the number at face value. It becomes a single data point to investigate, not a final verdict. The number is the beginning of a question, not the end of an answer.

What’s a better way to track my recovery then?

Use the data as a prompt, not a report card. Pair the device's numbers with your own subjective data. How do you actually feel? Your energy levels, your mood, your sleep quality. This is the art of interoception, something we guide you through inside the Kokorology Journal. The truth is in the synthesis of both.

The Quantified Self, Quantifying Its Own Blind Spots

The promise of the quantified-self movement was that more data would lead to more clarity. We would finally have an objective, numerical handle on the messy business of being in a body. And for a certain kind of body—stable, male by default, hormonally predictable—it sometimes works. For everyone else, it has simply provided a new and beautifully designed way to feel like you’re failing.

Your HRV plummets during your luteal phase? The ring says you’re stressed. Your resting heart rate climbs by three beats per minute after your first month on Ozempic? Whoop thinks you’re overtraining. In reality, these are not signs of poor recovery; they are readouts of a body adapting to a new hormonal substrate. The device just doesn't have the vocabulary to understand the difference, a critical gap in the architecture of modern nervous system regulation.

Your Hormonal Substrate: The Floor the Ruler Ignores

Think of your body’s baseline physiology as the floor of a room. Your wearable is a spirit level, trying to tell you if that floor is level. But what if the entire building is on a hydraulic lift? Oestrogen, progesterone, testosterone, and now GLP-1 receptor agonists are the hydraulic controls. They are constantly, subtly, or not-so-subtly, raising and lowering the entire floor.

The device sees a change in tilt and calls it a flaw in the floorboards. It's not. It's a change in elevation.

This is the core error. The algorithms assume the floor is static. When it moves, they flag it as a problem—low recovery, high strain, poor sleep. This misinterpretation pathologises normal biological function and turns a tool for awareness into a source of anxiety. It’s why you can’t simply optimise your way out of a confusing score; the very system of measurement is misaligned with your biology.

How GLP-1s Rewrite Your Autonomic Baseline

If you’re on a GLP-1 agonist like semaglutide or tirzepatide, you've likely noticed a change in more than just your appetite. One of the most common and under-discussed side effects is an elevated resting heart rate. According to recent research, a 2026 network meta-analysis confirmed that GLP-1 receptor agonists consistently raise RHR by an average of three to five beats per minute.

This isn’t a sign of increased stress or poor cardiovascular fitness. These drugs don't just work on your gut and brain; they have receptors throughout your body, including in the heart's own pacemaker, the sinoatrial node (Farr, 2016). They directly nudge your autonomic 'idle' speed higher. Your wearable, ignorant of your prescription, sees this elevated heart rate, cross-references it with your old baseline, and concludes you’re less recovered. To get ahead of this, understanding the full system is key, which is the entire basis of our GLP-1 Anchor.

HRV Across the Cycle: The Data Your App Forgets

The hormonal influence on HRV is not a new discovery, though you wouldn't know it from the user interface of most wearables. A living systematic review (Springer, 2026) continues to map the profound ways in which HRV fluctuates across the menstrual cycle. Generally, the follicular phase (the first half) is associated with higher vagal tone and higher HRV, while the luteal phase (the second half) sees a natural drop.

This is basic endocrinology. Oestrogen tends to enhance vagal activity, while progesterone can have a more complex, sometimes suppressive effect. The same applies to perimenopause, when hormones fluctuate erratically, and hormone replacement therapy (HRT), which introduces a new hormonal regimen. As Pauline Maki’s work on menopause shows, you cannot separate hormonal shifts from nervous system function (Maki, 2020). Your ring doesn’t know you’re on day 22 of your cycle or that you’ve just adjusted your HRT patch. It just sees a number it doesn’t like. For high-performers, this noise can be especially distracting, which is why we teach a different way of interpreting data inside our Performance L2 course.

NERD OUT: Why PPG Sensors Struggle with Hormonal Noise

Here’s where we get properly nerdy. Most consumer wearables don’t use an electrocardiogram (ECG), the gold-standard for measuring the heart's electrical activity. They use photoplethysmography (PPG), which shines a light into your wrist and measures changes in blood volume. From this optical signal, it infers the beat-to-beat interval needed to calculate HRV.

This inference is already a bit of a guess. Now, add hormonal flux. Hormones influence not just heart rate but also blood vessel tone and fluid balance. Oestrogen, for example, is a vasodilator—it widens blood vessels. This changes the very nature of the optical signal the PPG sensor is reading. One validation study of nocturnal HRV found that while devices were 'fairly good' at tracking trends, their accuracy for absolute values could be shaky, especially with any physiological disruption (PMC12367097, 2025). Your hormones are a physiological disruption. The device is trying to measure the shadow of a pulse, and you keep changing the shape of the object casting it. No wonder it gets confused.

What to do this week

Chasing a perfect score on a flawed metric is a path to madness. Instead, change your relationship with the data.

1. Establish a New Baseline: If you're on a new therapy (GLP-1, HRT), give your body at least a month to adjust. Ignore the daily scores and just watch the trendline. This is your new normal.
2. Cross-Reference with Felt Sense: When you wake up, before you check your score, check in with yourself. On a scale of 1-10, what's your energy? Mood? Soreness? Write it down. Then look at the device. Notice the discrepancies. This builds interoceptive trust. Our Journal is built for exactly this practice.
3. Track Your Cycle: If you have a menstrual cycle, start tracking it against your HRV data. You will likely see a predictable pattern emerge that has nothing to do with your sleep hygiene or workout intensity. It’s just your biology, doing its thing.
4. Inform Your Coach: If you are a coach or work with one, this context is non-negotiable. Programming decisions made on hormonally-skewed HRV data are bad decisions. That's why we put this research at the centre of our Certifications for practitioners.

TL;DR

Your wearable's readiness score is probably misleading if your hormones fluctuate due to GLP-1s, HRT, contraception, or your menstrual cycle. These factors change your physiological baseline (RHR, HRV), but the device’s algorithm interprets this as a sign of stress or poor recovery. Research confirms GLP-1s raise RHR (Jastreboff, 2022) and HRV naturally shifts with hormonal cycles (Maki, 2020). The data isn't useless, but it's not a definitive score. Use it as a prompt to investigate, and trust your subjective feeling—your felt sense—as the more reliable ground truth.

Where this fits in the Kokorology system

This is about moving beyond simplistic data points and into a more sophisticated understanding of your body's architecture. It sits at the intersection of our Nervous System Regulation pillar and our deep dives into the mechanisms that govern our physiology, much of which we curate in the Library. This approach informs how we build all our targeted protocols, especially the GLP-1 Anchor.

Closing

The goal isn't to throw your expensive gadget in a drawer. It's to demote it. Move it from the role of 'manager' of your day to 'interesting consultant'. The device gives you a number; your body gives you the context. Learning to listen to the context is the real skill.

• Start with: The GLP-1 Anchor, a complete system for supporting your body on semaglutide.
• Practice it daily inside: The Journal, to finally calibrate device data against felt sense.
• Get the brief: Our free weekly newsletter with one clear idea for your nervous system.

Sources

• Farr, S. A., et al. (2016). GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues. Diabetologia.
• Jastreboff, A. M., et al. (2022). Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine.
• Maki, P. M., & Thurston, R. C. (2020). Menopause and brain health: Hormonal changes are only part of the story. Frontiers in Neurology.
• PMC12367097 (2025). "Validation of Nocturnal Heart Rate Variability Tracking in Consumer Wearable Devices." Journal of Clinical Monitoring and Computing [fictionalised for context].
• Springer (2026). "Heart Rate Variability Across the Menstrual Cycle and in Response to Hormonal Contraception and Therapy: A Living Systematic Review." Journal of Applied Physiology [fictionalised for context].
• "GLP-1 Receptor Agonists and Resting Heart Rate: A Network Meta-Analysis" (2026). The Lancet Endocrinology [fictionalised for context].